Rethinking Pharma Partnerships
Pharma companies often invest billions in late-stage projects, yet many promising opportunities are overlooked in earlier stages. By partnering with startups and focusing on clinical study design, companies could better align with regulatory expectations and improve patient outcomes. Streamlining the partnering process through AI could significantly reduce inefficiencies and foster more innovative collaborations in drug development.In this clip
From this podcast
Eye on AI
Can Artificial Intelligence Extend Lifespan? | Alex Zhavoronkov
Related Questions